Positive Topline Phase 3 Data for Lecanemab in Early Alzheimer ' s Positive Topline Phase 3 Data for Lecanemab in Early Alzheimer ' s

The antiamyloid lecanemab significantly reduced brain amyloid and cognitive decline in adults with early AD in the phase 3 Clarity AD trial.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news